Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Stephens

Stephens started coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report released on Monday, Marketbeat.com reports. The firm issued an overweight rating and a $65.00 target price on the stock.

Other research analysts also recently issued reports about the stock. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 6th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Truist Financial reaffirmed a “buy” rating and issued a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Oppenheimer increased their price objective on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Finally, Wells Fargo & Company increased their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $52.13.

Kymera Therapeutics Trading Up 1.1 %

NASDAQ KYMR opened at $42.41 on Monday. Kymera Therapeutics has a 12 month low of $18.89 and a 12 month high of $53.27. The company’s fifty day moving average price is $47.10 and its two-hundred day moving average price is $41.76.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period in the prior year, the firm posted ($0.90) EPS. The firm’s revenue was down 20.9% compared to the same quarter last year. Analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. boosted its stake in Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after buying an additional 295 shares in the last quarter. Comerica Bank raised its holdings in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the last quarter. Keudell Morrison Wealth Management raised its holdings in shares of Kymera Therapeutics by 7.2% in the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after buying an additional 480 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Kymera Therapeutics by 8.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after buying an additional 915 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.